Multi-omics studies are believed to provide a more comprehensive picture of a complex biological system than traditional studies with one omics data source. However, from a statistical point of view data integration implies non-trivial challenges. In this review, we highlight recent statistical inference and learning techniques that have been devised in this context. In the first part of our article, we focus on techniques to identify a relevant biological sub-system based on combined omics data. In the second part of our article we ask, in which way integrated omics data could be used for better personalized patient treatment in a supervised as well as unsupervised learning setting. Different classes of algorithms are discussed for both application tasks. Existing and future challenges for data integration methods are pointed out.
INTRODUCTION
During the last years there has been an increasing interest to analyze multiple, heterogeneous omics data in an integrated manner in order to gain a more and more comprehensive picture on complex biological systems [1] .
For example, large scale initiatives such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) [2] now provide transcriptomics, methylomics, proteomics and genomics data of hundreds of patients for several cancer entities, allowing novel insights into cancer biology [3] . Historically, expression QTL analysis (see systematic list of abbreviations in Table 1 ) can be seen as one of the first approaches combining two data modalities, namely information on genetic variations with gene expression [4, 5] .
While most authors agree on the chances of omics data integration, the associated challenges have been discussed under a varying point of view over the last decade: While in 2006 data availability was seen as one of the big issues [6] , later papers mentioned statistical challenges, such as the risk of overfitting [7] , and the difficulties associated with different technical platforms, for example differing normalization protocols and batch effects [8] .
Altogether the challenges for integrating heterogeneous omics data may be summarized as follows: omics data of different modality (e.g. transcriptomics vs. proteomics) are measured with different techniques. Hence, these data have differing numerical types (e.g. discrete counts vs. continuous signals) and scales, coupled with large differences in the number of measured features (several hundreds of thousands of SNPs vs. few hundreds of miRNAs). Furthermore, each technical platform has another noise level and sensitivity. Consequently, naive merging of heterogeneous omics data increases the dimensionality of the data and thus increases the chance to produce false positive hypothesis testing results. In a machine learning setting the chance increases to overfit the data. In order to circumvent these problems the key question is therefore, how to identify and combine relevant features from each data modality in a way that respects known biological dependencies.
The goal of this review is to give an overview about recent statistical inference and learning techniques that have been devised to address this issue. Previous reviews focused on specific applications of data integration in the cancer field [8] and genetics [9] , on the relevance of data integration for personalized medicine [10] , on technical aspects of network integration [11] and dimensionality reduction [12] , or provided a high-level view on ongoing research projects [13] . A mathematically oriented review can be found in [14] . As opposed to our paper, the authors emphasize specific mathematical details of selected methods, whereas we try to characterize the overall methods landscape. More specifically, we here highlight two aspects: In the first part of our review we focus on learning and modelling dependencies between different data modalities on the level of individual features. That means the aim is to identify a relevant biological sub-system based on combined omics data. In the following section we ask, in which way integrated omics data could be used for personalized patient treatment in a supervised as well as unsupervised learning setting.
Abbreviation
Full throughout this paper. While this terminology is commonly used in the machine learning and statistical literature it might not be entirely clear to all researchers with non-computational background.
Furthermore, explanations could help to avoid misunderstandings due to partially ambiguous use of some terms in different scientific communities. Table 2 shows an overview about several frequently used terms together with explanations.
As already outlined in [13] "data integration" can have multiple meanings in different scientific contexts. Here we refer to data integration or data fusion as a statistical or machine learning based approach to extract information from multiple data sources / modalities (e.g. gene plus protein expression data). These information can be used to fit / train / learn statistical models. For example, such a model could be a classifier used to predict the disease state of a cancer patient. In general we distinguish between supervised and unsupervised model learning. In supervised learning we train a model based on a possibly large number of omics features coupled with the known outcome / phenotype for each training sample. In the previous cancer example, training samples would be patients with measured omics data plus known disease state. Notably, supervised learning is not restricted to classification, but also real valued outcomes (e.g. disease severity scores, survival) can be predicted via regression models.
As opposed to supervised learning, unsupervised learning aims at inferring patterns from data without having access to a phenotype.
For example, unsupervised clustering of gene expression data from Glioblastoma Multiforme patients has been used to identify several disease subtypes [15] .
A general concern with all machine learning models is overfitting, meaning a good fit to the training data, but poor prediction performance on further test data at model application phase. Overfitting can be attributed to overly complex models compared to the limited amount of available training data. Hence, model training should a priori favor simpler models over more complex models. For example, this can be achieved via a mathematical technique called "regularization". Furthermore, in the omics field variable / feature selection is essential, because data samples (e.g. representing patients) are sparsely distributed in an extremely high dimensional space, which is spanned by measured omics features.
Hence, with typical number of training samples a huge set of different models could exist, which could equally well fit the data. The true model is thus typically non-identifiable without further background information. Reducing the number of features thus also reduces the set of possible models and thus lowers the chance to overfit the training data.
Notably, feature selection is not necessarily identical to differential expression analysis or similar techniques to identify most significant omics features. Hypothesis tests are typically conducted separately for each omics feature, yielding a p-value. However, non-significant features could be highly informative for a model in combination with other features, e.g. to separate two groups of patients with the help of a multi-variate classifier. Hence, it is important to think about feature selection from a multi-variate perspective.
Most machine learning models are trained by optimizing a certain objective function. However, some models also aim at describing the entire, multivariate statistical distribution, from which the training data has been drawn as samples. These models are known as probabilistic models. Many of these probabilistic models can be depicted as graphs, where nodes represent random variables and edges conditional statistical dependencies (graphical models). Examples thereof are Bayesian Networks.
Typical machine learning models are purely data driven, i.e. they extract statistical associations from training data without background information about the biological context. Therefore, extracted patterns may or may not correspond to any known biological mechanism. A conceptually different approach is thus to focus only on established biological knowledge, e.g. a given pathway or network structure, to which then biological data is mapped to qualitatively or quantitatively to better understand a biological system. Such an approach is called knowledge driven. Table 3 .
LEARNING AND MODELLING MOLECULAR
Probably the most straight forward approach to integrate heterogeneous omics data is an independent analysis of each omics data modality. As a second step, correspondences between relevant features based on biological background knowledge are investigated. For example, as a first step significant CNVs and gene expression changes can be determined.
In the second step significant CNVs can be mapped to genes, which are then overlapped with differentially expressed genes [16, 17] . This type of analysis can be extended to more than two data modalities: Sun et al. looked for overlaps between differentially expressed and differentially methylated genes as well as for regions with statistically significant copy number variations in breast cancer cells [18] . Chari et al. also integrated loss of heterozygosity profiles and investigated, in how far the direction of observed expression changes matched with CNV and DNA methylation status in different breast cancer cell lines [19] .
A principal limitation of sequential analysis is that relevant features from each dataset are only determined with respect to the phenotype.
Hence, there can be non-significant features, which nonetheless correlate well with features from another data modality. For example, a certain SNP could by itself not demonstrate a clear separation between two clinical groups, but nonetheless shows a clear statistical effect on gene expression. Such a feature is missed in sequential analysis. Moreover, significance cutoffs in each omics data modality are defined independently. Hence, features in the overlap can be biologically non-concordant just because truly relevant features are above the significant cutoff in one of the data sources. Likewise, false positive features can yield non-concordance.
Correlation, Covariance and Regression Based Techniques
Another approach is to directly look for significant correlations between features from different data modalities. For example, CNVs and gene expression can be correlated with each other [20, 21] 
Bayesian Networks
Bayesian Networks (BNs) belong to the family of graphical models and offer a completely probabilistic view on data integration.
BNs explicitly model conditional statistical dependencies between random variables [45] .
Typically, each random variable represents one molecular feature (e.g. a protein). Integration of different omics data modalities (e.g. gene and protein expression) can be performed by discretizing each dataset while including additional auxiliary indicator variables describing the biological context [46] . Another option is to use e.g. gene expression as primary data source and employ further data (such as protein-protein interactions, DNA-protein interactions, histone modifications or combinations of several sources) to construct informative network priors, which facilitate the identification of the true biological network from data [47] [48] [49] .
Arguably, one of the first applications of BNs for biological data integration can be found in Huttenhower and Troyanskaya [50] , where the authors presented a BN integrating gene expression and various functional and relational/interaction data in order to predict functional relationships between proteins.
As usual in BN modelling, the suggested method was based on a data discretization in order to harmonize differing data types and to allow for non-linear relationships between variables. Later work showed the possibility to integrate heterogeneous modalities on very large scale via a naive Bayesian classifier system with parameter regularization in order to predict protein functions [51] .
Another line of research within the BN framework focuses on extending the module network approach in order to decipher regulatory programs [52] . The essential idea behind the module network algorithm is to group genes based on co-expression. Within the BN framework random variables falling into one module share the same parameters and parents, hence yielding a significant reduction of model complexity and improvement of prediction performance compared to traditional BNs [53] . While the original module network algorithm was based on a greedy strategy to assign network nodes to modules, later variants introduced Gibbs sampling [54] and ensemble learning [55] . More recently, module network variants integrating gene expression data with SNPs [56] , CNVs [57] , miRNA and clinical [58] as well as potential further data [59] have been proposed. The key idea in all of these modifications is to employ data different from gene expression for selecting candidate drivers/regulators of specific gene modules.
Specific BN variants have also been employed for predicting miRNA and transcription factor combinations explaining gene expression changes based on joint gene and miRNA expression data [60, 61] . The authors of these papers treated regulator activities as hidden binary variables in a special kind of BN, in which the topology was defined by target gene prediction methods. Markov Chain Monte Carlo (MCMC) was then performed for Bayesian inference of these latent variables. miRNA and gene expression measurements were included as observed Gaussian variables. In [61] the author extended the approach further by Bayesian learning of the regulator-regulator dependency network.
Using Molecular Networks for Data Integration
Another line of research focuses on using biological networks as backbone for heterogeneous data integration.
Information about canonical pathways, protein-protein, protein-DNA as well as predicted miRNA-gene interactions can nowadays be found in large scale databases [62] [63] [64] [65] [66] [67] . Based on these resources molecular networks can be reconstructed and employed for mapping statistics (e.g. z-scores) of omics data. Accordingly, graph based algorithms can be employed for identifying relevant sub-networks [68] . Dittrich and co-workers interpreted this task as an instance of the Price Collecting Steiner Tree (PCST) problem and came up with a provably optimal solution via integer linear programming [69] . At the same time they demonstrated that in this way gene expression and other data modalities (e.g. clinical information) could be combined.
Another example is the work of Nibbe et al., who integrated gene and protein expression data with the help of a protein-protein interaction (PPI) network [70] . The authors first looked for differentially expressed proteins at the proteome level. In a second step they scanned potential interaction partners for synergistic dysregulation on mRNA level using a modification of Google's Page Rank algorithm in order to define candidate sub-network. In a last step these candidate sub-networks were then scored via a mutual information based approach.
Rather then generating and scoring sub-networks other researchers have focused on predefined pathways and gene sets.
Following this line of research Tyekucheva and colleagues proposed a meta analysis approach following separate gene set investigation for each data modality [71] . As an alternative method the same authors suggested a model based integration of gene-to-phenotype association scores using all data sources together, which is followed by gene set analysis of these scores. Tyekucheva and co-workers in this way were able to integrate gene expression and CNV data from glioblastoma multiforme patients.
In line with the meta analysis idea Sun et al. [72] and Kamborov et al. [73] developed tools, which combine gene set statistics of different data modalities via rank aggregation and consensus p-value method, respectively.
In contrast to the above described gene set analysis methods PARADIGM is a fully Bayesian approach, which takes into account the structure of a molecular pathway as well as further biological background knowledge [74] .
PARADIGM allows for annotating molecular network nodes with further functional information (e.g. "apoptosis") as well as information on molecule type (e.g. "DNA", "mRNA", "protein"). In PARADIGM activities of node are viewed as latent variables in a factor graph model. Given observed data, inference about the state of these latent variables is then performed via belief propagation. As a result pathway activities are estimated. The authors have demonstrated that their method is able to integrate mRNA and CNV data as well as additional miRNA and DNA methylation information [75] .
Wachter et al. recently published an R-package, which specifically focuses on the integration of transcriptomics and proteomics data via pathways, protein-protein and protein-DNA interactions [76] . These information are used to link differentially expressed proteins to transcription factors as well as pathways. At the same time differentially expressed transcripts are linked to transcription factors and pathways. In a consensus step all results are combined either via simple overlap analysis, via a shortest-path based approximate Steiner tree algorithm [77, 78] or via a dynamic Bayesian Network structure learning algorithm [79] .
UTILIZING INTEGRATED OMICS DATA FOR PERSONALIZED MEDICINE Clinical Outcome Prediction
One of the primary goals of personalized medicine is to stratify patients into clinically relevant sub-populations based on suitable biomarker signatures. An overview about the associated statistical learning techniques discussed in this section can be found in Table 4 .
During the last decade computational research in the personalized medicine area has mainly focused on learning predictive models based on one data modality (e.g. gene expression), possibly also in combination with biological background knowledge (see [80] for a review). The advent of multiple, heterogeneous omics data modalities from the same patient (e.g. somatic mutations plus gene expression data) now raises the question, whether predictive models utilizing several combined data sources could improve prediction performance. Hence, the primary objective for omics data integration in personalized medicine is not to identify biologically relevant molecular networks, as discussed in the last Section, but to enhance model learning and prediction performance.
In the machine learning community traditionally three general strategies for data integration are distinguished [81, 82] : Early integration methods focus on extraction of common features from several data modalities, resulting into one integrated data matrix. In a second step conventional machine learning methods can then be applied. Late integration algorithms first learn separate models for each data modality and then combine predictions made by these models, for example with the help of a meta-model trained on the outputs of data source specific sub-models. The latter strategy is called stacking [83] . Intermediate integration algorithms are the youngest branch of data fusion approaches. The idea is to join data sources while building the predictive model. An example of this strategy is Support Vector Machine (SVM) learning with linear combinations of multiple kernel functions [84] .
All three data integration strategies have been applied in the area of personalized medicine: Pittman et al. [85] integrated clinical and gene expression data into a Bayesian decision tree classifier to predict breast cancer prognosis. Following an early integration approach the authors first summarized gene expression data into meta-genes [86] , which were then joined with clinical variables. Selection of relevant variables was carried out via forward selection.
Boulesteix et al. first used partial least squares (PLS) regression to extract features from gene expression data [87] . These features were then combined with clinical variables to train a Random Forest classifier for predicting breast and colorectal cancer outcome. In a similar vein Cao et al. [88] proposed a mixture of experts model to jointly model the effect of gene expression and patient clinical data to predict patient outcomes, they concluded that using gene expression data can provide valuable insights to understanding survival mechanisms by identifying prognostic biomarkers.
Gevaert et al. [89] employed a Bayesian Network to combine clinical and gene expression based on the 70 gene breast cancer signature by van't Veer et al. [90] .
The authors compared an early integration strategy based on simple pasting of data matrices with an intermediate and a late strategy. In the intermediate integration the authors first learned separate BN structures for each data sources and then join these networks based on the node representing the clinical outcome they had in common. In the late strategy only predictions by the two separate BN models were weighted and aggregated. The authors found the intermediate strategy to be most promising.
Daemen and co-workers suggested the use of a multiple kernel learning (MKL) framework to predict disease outcome of rectal cancer based on gene and protein expression data, and of prostate cancer based on transcriptome and CNV data [91] . Within the MKL framework separate kernel functions were defined for each omics data modality.
A linear combination of these kernels was then employed to train a least squares SVM (LS-SVM). The authors reported a better prediction performance of this intermediate data integration strategy compared to model stacking.
Following again the idea of MKL, Thomas et al. suggested a weighted LS-SVM classifier to combine gene expression and clinical data [92] . Compared to models built on each individual data modality as well as compared to an early integration strategy using generalized singular value decomposition, the authors found a significant improvement of their approach for predicting breast cancer outcome.
Wang et al. [93] developed an integration scheme based on probabilistic graphical models and Bayesian inference. Their iBAG algorithm (integrated Bayesian Analysis) combines miRNA, DNA methylation and mRNA data to predict patient survival of Glioblastoma Multiforme (GBM) patients. Their approach explicitly takes into account the biological relationship between different data modalities. The authors identified separate gene sets related to disease outcome and demonstrated better prediction power to detect disease related genes than non-integrative methods.
Gade et al. first constructed a correlation weighted bipartite miRNA-target gene graph [94] . This graph was then used to guide feature selection with a component-wise likelihood boosting algorithm for predicting prostate cancer outcome [95] . Going one step further other authors also considered protein-protein interaction information [96] . Their method first smoothes marginal t-statistics of genes and miRNAs over the structure of the integrated PPI and miRNA-target gene network via random walk kernels.
Most relevant features are then determined via a permutation test. Subsequently a conventional SVM classifier is trained. The authors demonstrated the benefit of this approach compared to stacking for predicting disease prognosis in several cancers.
Arguably one of the most advanced but also computationally costly approaches for intermediate data integration in the field of personalized medicine has recently been suggested by Zitnik and Zupan [97] . The authors combined gene expression and histological data from animals and human with protein-protein interactions and GO annotation to predict liver injury induced by chemicals. This was done based on a constrained matrix tri-factorization algorithm suggested by the same authors [98] .
Vliet et al. made a comparison of several integration strategies (pasting of feature matrices, linear combination of distance measures or kernel functions, stacking) and classifiers to predict breast cancer outcome [99] . The authors reported most success via an intermediate strategy using a nearest mean classifier our via a late strategy using a logical OR function.
Unsupervised Patient Subgroup Detection
Apart from supervised patient stratification using defined clinical endpoints (e.g. survival times), a lot of effort has been made to detect patient sub-populations in a completely unsupervised manner based on molecular data. An example of this approach is the detection of four different molecular subtypes of Glioblastoma Multiforme (GBM) patients based on gene expression data by Verhaak et al. [3] . As more molecular data modalities from the same patient become available now, many authors explored the possibility of fusing these data for discovering stronger patterns (see [100] for a review)
Akin to the case of supervised learning for patient stratification, unsupervised data fusion approaches can be broadly classified into three groups, which involve early, late and intermediate integration schemes. Early integration methods work with a joint feature matrix and modify traditional clustering algorithms, such as k-means, to calculate a weight for each data source [101] .
Late integration combines patient similarity matrices obtained from independent clusterings of distinct data types. Intermediate integration methods typically aim for extracting common features from different data modalities combined with clustering of patients.
An example of an intermediate integration strategy is non-negative matrix factorization (NMF) [102] . The idea behind NMF is to factorize a data matrix into a product of two matrices, one indicating discriminative feature combinations between clusters and one indicating cluster assignments of patients. While originally NMF was designed to work with one data modality only, later work has extended the approach to simultaneous clustering of several data types. For example, Zhang et al. used an extended NMF framework to cluster 385 ovarian cancer patients based on joint gene expression, DNA methylation and miRNA profiles [103] .
Another popular intermediate integration approach is the iCluster method by Shen et al. [104, 105] . This technique combines ideas from sparse matrix decomposition and latent factor models and has also remarkable similarities to probabilistic PCA [106] and k-means [107] . Furthermore, the iCluster method can be seen as a special case of Bayesian canonical correlation analysis with a sparsity prior for the coefficient matrix [108] , facilitating model identifiability and interpretability. In [105] the authors used iCluster to integrate gene expression, DNA methylation as well as CNV data of Glioblastoma Multiforme (GBM) patients. The iCluster method treats information from all patients with the same confidence, which may lead to erroneous results, if there are patients with dis-concordant information from different omics data modalities.
The latter issue was taken up by Yuan et al. [109] , who developed a Patient Specific Data Fusion (PSDF) model, which gives different patients separate weights within a non-parametric Bayesian framework. A unique aspect of PSDF is that it allows for the separation of concordant and dis-concordant signals from patients and unlike iCluster does not force patients to cluster together. The obtained disease subtypes via PSDF were reported to be prognostically relevant by the authors. A limitation of the PSDF method is in the required data discretization, which may lead to considerable loss of information. Similar to the PSDF method Kormaksson et al. [110] proposed a mixture-model for integrative clustering of gene expression and DNA methylation data. Unlike PSDF, the method does not require data discretization. However, a limitation is the assumption of statistical independence of molecular features.
Another recent mixture model approach is the MDI (Multiple Data Integration) approach by Kirk et al. [111] and Savage et al. [112] . Following a Bayesian non-parametric clustering approach MDI assumes a Dirichlet Process Prior over cluster assignments. Moreover, and in contrast to PSDF, MDI learns exact dependencies between the different data sources as a directed acyclic graph. This implicitly results in a preference to put patients into the same cluster, if they tend to group together in each of the different data sources. However, at the same time each data source still retains its own clustering, reflecting the fact that different molecular data may express partially non-concordant patient groupings. Savage et al. [112] used the MDI model to integrate genomic, epigenomic and transcriptomic information of GBM patients and reported clinically relevant disease sub-types. MDI is flexible in modelling continuous (e.g. gene expression) as well as discrete (e.g. CNVs) data. A limitation is the assumption of statistical independence of molecular features.
Generative modelling approach, such as MDI and PSDF, require to express explicitly the joint statistical distribution over different data modalities. This complication is avoided in late integration techniques. Examples are Similarity Network Fusion (SNF) [113] and Multiview Genomic Data Integration (MVDA) [114] . These techniques use independent clustering algorithms for each data modality and aggregate results of patient similarity matrices from each data source. Thus, late integration potentially allows for incorporating thousands of features for each data modality. Furthermore, late integration techniques are typically more robust to small sample sizes. A limitation is the difficulty to explicitly model dependencies between data modalities. The SNF method models patient similarities as networks with nodes representing patients. Each data modality generates its own network, and these networks are then fused into a consensus network using a message-passing algorithm. The authors in this way integrated gene expression, DNA methylation as well as miRNA profiles over five cancer datasets and performed graph clustering on the consensus network to identify disease subtypes. The MVDA approach [114] concatenates patient-patient similarity matrices obtained from different data sources and then uses matrix factorization of the concatenated matrix to come up with a consensus clustering.
Biclustering is yet another popular statistical technique for simultaneous clustering of the rows and columns of a data matrix and has recently also been employed for data fusion.
The original method along with its modifications has since many years found several applications in biological data analysis (see [115] for a comprehensive review).
Recently, Bunte et al. [116] developed a novel bi-clustering algorithm to cluster cancer cell lines treated with different drugs while including CNV, DNA methylation, mRNA, protein abundance and exome sequencing information. The model is based on the previous work of the same group of authors on the Group Factor Analysis Model [117] . Another technique based on biclustering has been proposed by Sun et al [118, 119] . Their method is based on sparse singular value decomposition (SSVD) and was applied to combine SNP information with clinical data for disease subtyping and identification of subtype-specific genotype variations.
CONCLUSION
Fusion of heterogeneous omics data modalities is widely believed to improve our understanding of biological systems and to enable better personalized medicine.
However, statistical data integration is associated with non-trivial challenges resulting from differing numerical and statistical properties of individual omics data modalities. These challenges come in addition to all the well known issues with individual omics data, namely high dimensionality at low sample size and high noise level. As multi-omics studies become more and more common practice, there is a growing need for appropriate statistical learning and inference techniques. The goal of this review is to shed light on the current state of methodology in the field. We are aware of the fact that our review is limited at this point. Techniques not covered here include e.g. ODE based models in systems biology [120] . Moreover, we restricted ourselves to the question of integrating multiple -omics data modalities. Hence, we did not address genomic data fusion approaches, which have been e.g. applied in the context of disease gene prioritization [121] .
Multi-omics data are believed to reflect more information about a biological sub-system than a single data modality. Hence, a considerable number of approaches focus on learning and modelling dependencies between molecular features of different modalities. Most techniques within that family follow a knowledge driven approach, which employs biological networks as a backbone. These methods integrate data and biological knowledge in a far better and more consistent way than purely sequential analysis approaches. However, despite the success of methods such as PARADIGM the knowledge driven framework is limited by the incompleteness of current biological knowledge.
Moreover, biological networks are in principle cell type and biological condition dependent, which is often ignored in practice.
On the other hand methods within a BN learning scheme have been developed, such as extensions of the module network algorithm, which allow for a greater flexibility at this point, but are confronted with the non-trivial challenges (including non-identifiability) of network structure learning. Correlation and covariance based methods, such as sparse CCA, make considerably less assumptions than knowledge driven methods, while being at the same time significantly less computationally demanding than BN based approaches. Moreover, these methods do not face identifiability problems up to the same degree than BN based approaches. However, interpretation of feature combinations extracted by sparse CCA is typically more difficult and may require in addition biological networks in a secondary analysis step, resulting in similar limitations than mentioned above for knowledge driven approaches.
In the area of personalized medicine two goals of multi-omics data integration are better supervised prediction of clinical outcomes and better unsupervised identification of so far unknown patient sub-populations. For both types of machine learning tasks available approaches can be categorized as early, intermediate or late phase integration. The majority of methods follow the intermediate phase integration scheme, because it is believed that in this way most of the dependencies between different data modalities can be captured. Specifically in the unsupervised setting many approaches follow a probabilistic modelling scheme, whereas for supervised clinical outcome prediction the picture of applied techniques is more diverse. Arguably one of the most advanced methods in the field is the matrix tri-factorization method by Zitnik and Zupan [97] , which makes use of known relationships (physical, functional, semantic, ...) between molecular entities, patients and diseases.
Of course, each of the methods in the two above discussed application domains of multi-omics data integration makes specific assumptions, which are often difficult to verify or falsify in practice, partially due to the high dimensionality of the data. Moreover, apart from supervised machine techniques, for most of the above mentioned models there is no clear and objective performance metric for assessing their actual success. Typically, authors thus rely on simulations and biological interpretation of results on real data to validate their methods. Altogether the choice of an appropriate integration approach should thus depend on different factors, such as the amount and quality of biological background knowledge for the particular research question and the amount and quality of available data.
Fewer data with lower quality will generally require less complex models than high quality datasets with larger sample size. Furthermore, the level of expertise of the modeler is in practice a non-negligible factor [122] .
A general issue with all multi-omics approaches, which is specifically true in the personalized medicine area, is that for one and the same biological sample not always all omics data types have been systematically measured. For example, in TCGA for many patients and cancer types gene expression data is not always matching with somatic mutations and DNA methylation. Since most current integration strategies focus only on those samples, for which all data modalities are available, there is a loss of information. Hence, new integration methods, possibly utilizing ensemble learning techniques, should focus on reducing this loss of information, while at the same time appropriately handling biases resulting from unequally balanced data types.
The above mentioned aspect may be viewed in the light of the current Big Data discussion: While there is on one hand an evident data explosion in modern biology and medicine -think e.g. about data volume for one whole genome patient sequencing -on the other hand in many cases we still lack the data to cover a single relevant biological phenomenon up to sufficient level. This paradoxical situation in modern biology and medicine can be partially attributed to the enormous complexity of biological systems coupled with still existing limitations of measurement techniques and costs. Future developments in biotechnology may help to overcome some of these limitations and allow for obtaining a more and more comprehensive picture of biology. It is likely that these developments in turn will increase the relevance of heterogeneous data integration methods. 
